Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease
Objective: The aim of this study was to evaluate the mid-term efficacy of drug-coated balloons (DCB) in percutaneous coronary intervention (PCI) in two different pathophysiologic scenarios. Background: There are different underlying pathological processes in coronary artery disease. Mid-term safety...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/7/1859 |
| _version_ | 1797438828090228736 |
|---|---|
| author | Gal Sella Gera Gandelman Nicholay Teodorovich Ortal Tuvali Omar Ayyad Haitham Abu Khadija Dan Haberman Lion Poles Michael Jonas Igor Volodarsky Jacob George Alex Blatt |
| author_facet | Gal Sella Gera Gandelman Nicholay Teodorovich Ortal Tuvali Omar Ayyad Haitham Abu Khadija Dan Haberman Lion Poles Michael Jonas Igor Volodarsky Jacob George Alex Blatt |
| author_sort | Gal Sella |
| collection | DOAJ |
| description | Objective: The aim of this study was to evaluate the mid-term efficacy of drug-coated balloons (DCB) in percutaneous coronary intervention (PCI) in two different pathophysiologic scenarios. Background: There are different underlying pathological processes in coronary artery disease. Mid-term safety and efficacy of DCB approach is still limited. Methods: Medical records of all consecutive patients undergoing DCB were evaluated. The primary endpoint was the rate of clinically driven target lesion revascularization (TLR) after 24 months. Results: Between January 2011 and December 2017, 442 patients were included, representing 4.4% of all PCIs in our institution. A total of 460 DCB lesions were treated, of which 328 (71.3%) were de novo and 132 (28.7%) were combined bare metal or drug-eluting stents with in-stent restenosis (ISR). The patients’ mean age was 66.2 ± 11.7 years with a diabetes prevalence of 45.3%. The TLR rate was lower in the de novo group (5.3%) compared to the ISR group (9.4%) (<i>p</i> = 0.04). No differences were observed in major adverse cardiovascular events (MACE) between the de novo group (38.9%) and ISR group (42.5%) (<i>p</i> = 0.47). No significant differences were detected in the TLR occurrence in the subgroup analysis. Conclusion: Our extended experience demonstrates that the mid-term DCB approach in these two pathophysiologic settings represent a reasonable option, with low TLR rate. |
| first_indexed | 2024-03-09T11:43:56Z |
| format | Article |
| id | doaj.art-dbad09c2fa49479ebac3fae943ac7ab0 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T11:43:56Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-dbad09c2fa49479ebac3fae943ac7ab02023-11-30T23:27:52ZengMDPI AGJournal of Clinical Medicine2077-03832022-03-01117185910.3390/jcm11071859Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery DiseaseGal Sella0Gera Gandelman1Nicholay Teodorovich2Ortal Tuvali3Omar Ayyad4Haitham Abu Khadija5Dan Haberman6Lion Poles7Michael Jonas8Igor Volodarsky9Jacob George10Alex Blatt11Heart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelHeart Center, Kaplan Medical Center, Rehovot, Hebrew University, Jerusalem 91905, IsraelObjective: The aim of this study was to evaluate the mid-term efficacy of drug-coated balloons (DCB) in percutaneous coronary intervention (PCI) in two different pathophysiologic scenarios. Background: There are different underlying pathological processes in coronary artery disease. Mid-term safety and efficacy of DCB approach is still limited. Methods: Medical records of all consecutive patients undergoing DCB were evaluated. The primary endpoint was the rate of clinically driven target lesion revascularization (TLR) after 24 months. Results: Between January 2011 and December 2017, 442 patients were included, representing 4.4% of all PCIs in our institution. A total of 460 DCB lesions were treated, of which 328 (71.3%) were de novo and 132 (28.7%) were combined bare metal or drug-eluting stents with in-stent restenosis (ISR). The patients’ mean age was 66.2 ± 11.7 years with a diabetes prevalence of 45.3%. The TLR rate was lower in the de novo group (5.3%) compared to the ISR group (9.4%) (<i>p</i> = 0.04). No differences were observed in major adverse cardiovascular events (MACE) between the de novo group (38.9%) and ISR group (42.5%) (<i>p</i> = 0.47). No significant differences were detected in the TLR occurrence in the subgroup analysis. Conclusion: Our extended experience demonstrates that the mid-term DCB approach in these two pathophysiologic settings represent a reasonable option, with low TLR rate.https://www.mdpi.com/2077-0383/11/7/1859coronary interventionneoatherosclerosisstent thrombosisTLRadvantages |
| spellingShingle | Gal Sella Gera Gandelman Nicholay Teodorovich Ortal Tuvali Omar Ayyad Haitham Abu Khadija Dan Haberman Lion Poles Michael Jonas Igor Volodarsky Jacob George Alex Blatt Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease Journal of Clinical Medicine coronary intervention neoatherosclerosis stent thrombosis TLR advantages |
| title | Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease |
| title_full | Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease |
| title_fullStr | Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease |
| title_full_unstemmed | Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease |
| title_short | Mid-Term Clinical Outcomes Following Drug-Coated Balloons in Coronary Artery Disease |
| title_sort | mid term clinical outcomes following drug coated balloons in coronary artery disease |
| topic | coronary intervention neoatherosclerosis stent thrombosis TLR advantages |
| url | https://www.mdpi.com/2077-0383/11/7/1859 |
| work_keys_str_mv | AT galsella midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT geragandelman midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT nicholayteodorovich midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT ortaltuvali midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT omarayyad midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT haithamabukhadija midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT danhaberman midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT lionpoles midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT michaeljonas midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT igorvolodarsky midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT jacobgeorge midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease AT alexblatt midtermclinicaloutcomesfollowingdrugcoatedballoonsincoronaryarterydisease |